Research programme: anticancer therapeutics - OSI Pharmaceuticals/SGX Pharmaceuticals
Latest Information Update: 06 Oct 2010
At a glance
- Originator OSI Pharmaceuticals; SGX Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Aug 2005 Structural GenomiX is now called SGX Pharmaceuticals
- 08 Sep 2003 Preclinical trials in Cancer in USA (unspecified route)